ERK1/2 inhibitor 11 , CAS No.E1418378

CAS: E1418378 Cat. No.: E1418378 분자식: C15H18N4O2S 분자량: 318.39
주문 가능
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
크기
USA
독일 (EU)*
가격
수량
1mg
E1418378-1mg
주문제작 · 8~12주
Enter a quantity for the sizes you want to add.

개요

ERK1/2 inhibitor 11 (compound L6) is a dual inhibitor of ERK1/2 , lending to DSB accumulation and ERK1/2 expression degradation. ERK1/2 inhibitor 11 lowers the levels of BCL-2 , and induces DNA damage by inhibiting PARP and ERK1/2. ERK1/2 inhibitor 11 activates caspase 3 to inducing apoptosis..

사양

보관 조건
Store at -20°C
배송
Ice chest + Ice pads
이 제품은 콜드 체인 배송이 필요합니다.지상 및 기타 경제 서비스는 사용할 수 없습니다.
작업 유형
ACTIVATOR
이름과 식별자
분자량
318.39

고급 데이터

인증서(CoA, COO, BSE/TSE 및 분석 차트)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
자주 묻는 질문과 기사
솔루션 계산기
리뷰

고객 리뷰

Application Protocols

There are no item-specific, validated application protocols provided for this product. The following are general, non-binding examples for planning purposes only. Adjust based on internal SOPs and empirical optimization.

Example 1: Biochemical ERK1/2 inhibition assay (general)

  • Prepare a 10 mM stock in DMSO. Perform 10-point 3-fold serial dilutions.
  • Assay buffer: 50 mM HEPES pH 7.4, 10 mM MgCl2, 0.01% Tween-20, 1 mM DTT (if compatible).
  • Add ERK1/2 enzyme and substrate peptide; initiate with ATP at near-Km.
  • Incubate 30 min at 30°C; quantify product via ADP-Glo or equivalent.
  • Fit dose–response (four-parameter logistic) to derive IC50.

Example 2: Cellular pathway modulation (general)

  • Seed cells (e.g., MAPK-active line) and allow adherence.
  • Treat with serial dilutions maintaining constant DMSO (≤0.1–0.5%).
  • Stimulate (if applicable) with growth factor; harvest at defined times.
  • Analyze p-ERK or downstream substrates (e.g., p-RSK) by Western blot or AlphaLISA.

Controls and QC:

  • Include vehicle control, unrelated kinase inhibitor control, and if possible a known ERK inhibitor as a reference standard.

Note: These examples are generic and not specific to this SKU; consult the product’s CoA/SDS and perform preliminary range-finding studies.

Biological Roles

Context: The product name indicates an ERK1/2 pathway inhibitor intended as a research tool. No item-specific potency, selectivity, or mechanism data are provided. The following describes ERK biology and typical research uses in general terms (literature background, not specific to this SKU).

  • Pathway overview: ERK1 (MAPK3) and ERK2 (MAPK1) are serine/threonine kinases within the RAS–RAF–MEK–ERK cascade. They transduce extracellular stimuli to regulate transcription, cell cycle progression, differentiation, and stress responses.
  • Activation cycle: ERK1/2 are activated by dual phosphorylation (TEY motif) by MEK1/2, then phosphorylate numerous substrates (e.g., RSKs, ELK1, c-Fos) in cytosol and nucleus.
  • Inhibitor classes: Literature reports ATP-competitive inhibitors that bind the catalytic site and allosteric inhibitors that modulate activation or substrate recognition. Selectivity against other kinases and pathway feedback dynamics are critical considerations in experimental design.
  • Research utility (general):
    • Acute pathway suppression to study feedback loops (e.g., relief of ERK-dependent negative feedback on RAF/MEK).
    • Dissection of phenotype dependencies on ERK output using genetic context models.
    • Benchmarking for assay validation (e.g., dose–response curves with p-ERK readout).

Caveats:

  • Off-target kinase inhibition can confound interpretation; orthogonal validation (genetic knockdown/CRISPR or multiple chemotypes) is recommended.
  • Cellular potency depends on permeability, efflux, and protein binding; these properties are unknown for this item and must be empirically determined.
Buffer Applications

This product is a bioactive small molecule and is not a buffering agent. Therefore, buffer capacity/pH systems are not applicable.

Practical handling notes (general, not item-specific):

  • For biochemical assays, prepare DMSO stocks and dilute into assay buffers (e.g., HEPES, Tris, or phosphate-buffered saline) ensuring the final organic solvent fraction is within tolerance for the assay system.
  • If solubility issues arise upon dilution, consider adding compatible surfactants at low percentages or using co-solvent strategies validated for the specific assay.

For buffer recipes, choose systems appropriate to your enzyme or cell model (e.g., HEPES pH 7.4 for kinase assays) independent of this compound.

Green Alternatives

As a bioactive screening compound, the main environmental considerations arise from solvent use and waste handling rather than the compound itself. Item-specific green metrics are not available.

Greener handling strategies (general guidance):

  • Prefer aqueous-compatible formats when feasible: use minimal DMSO and increase assay volume with buffered saline to keep final organic solvent ≤0.1%.
  • Replace DMF and dichloromethane in sample preparation with ethanol or ethyl acetate where chemically compatible.
  • Use micro-volume dispensing (acoustic or positive displacement) to reduce solvent consumption and plastic waste.

Comparison of common solvents for stock preparation (general):

  • DMSO: High solvency, low volatility, miscible with water; moderate EHS profile. Widely accepted for bioassays.
  • Ethanol: Renewable origin possible, higher volatility; compatibility may vary with cells/enzymes.
  • PEG400: Non-volatile, can enhance solubility; viscosity complicates pipetting and may affect assays.

Waste minimization:

  • Consolidate waste streams (halogenated vs non-halogenated) properly; avoid unnecessary dilutions that increase volume.
  • Validate minimal effective concentration in assays to limit compound usage.

Note: Without item-specific stability/solubility data, implement pilot experiments to optimize greener solvent systems while maintaining data quality.

Pharmaceutical Uses

No pharmacopeial status, formulation grade, or clinical use information is provided for this item. It is supplied strictly for research use only.

Relevant R&D contexts (general background, not item-specific claims):

  • Drug discovery tool: Employed as a reference or comparative agent in ERK1/2-targeted screening cascades and structure–activity relationship (SAR) studies.
  • Assay controls: Utilized to benchmark biochemical assay windows, cellular pathway inhibition (e.g., p-ERK reduction), and to qualify lot-to-lot consistency of reagents.
  • Bioanalytical standards: Potentially used as a method development standard for LC–MS quantification in matrix, pending availability of a certified reference—none is specified for this item.
  • Preformulation research: Exploratory solubility/permeability profiling, stability screening, and salt screening to inform medicinal chemistry—no item-specific data are provided.

Compliance and limitations:

  • Not for human or veterinary use. No implication of safety/efficacy is made.
  • Any translation to formulation studies should remain nonclinical and adhere to institutional and regulatory guidelines.

For any application beyond basic research (e.g., GLP studies), obtain full documentation (CoA, extended impurity profile, stability data) and qualify the lot accordingly.

Physical Properties

Item-specific physico-chemical data have not been provided for this SKU.

  • Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point (BP): Not specified for this item; refer to CoA/Spec Sheet.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
  • pKa: Not specified for this item; refer to CoA/Spec Sheet.
  • Refractive index: Not applicable/Not specified for this item; refer to CoA/Spec Sheet.

General guidance for ERK-pathway small molecules (literature/background, not item-specific):

  • Many kinase inhibitors are moderately lipophilic (cLogP ~2–5, literature), sparingly water-soluble at neutral pH, and typically handled as DMSO stock solutions (e.g., 10–50 mM) for biochemical or cell-based assays.
  • Ionizable centers (e.g., anilines, heteroarylpyrimidines) may permit salt formation to improve aqueous solubility; actual ionization for this compound is unknown.
  • Hygroscopicity and polymorphism can influence handling; no item-specific data are available.

Practical note: Prepare assay stocks according to your lab’s validation—determine solubility empirically (serial dilutions, visual inspection, nephelometry) and verify concentration by UV/Vis or LC-UV when possible. Always defer to the product’s CoA and SDS for definitive specifications.

Quality and Grades

Item-specific grade, purity, and stabilizer information are not provided in this listing.

  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • Stabilizers/antioxidants: Not specified for this item; refer to CoA/Spec Sheet.

Guidance on interpreting grades (general):

  • Screening library compounds are commonly provided at high chemical purity suitable for bioassays (often ≥95% by HPLC/LC–MS), but the exact threshold must be confirmed on the CoA.
  • If labeled as “HPLC grade” or “bioactive grade,” that typically denotes low levels of non-UV-absorbing impurities and suitability for cell/biochemical assays. Absence of such a label means no assumption should be made.
  • Residual solvents, counterions (if supplied as a salt), and water content may impact assay performance. These parameters are item-specific; confirm on the CoA.

Recommendations:

  • Verify identity by LC–MS (accurate mass) and purity by analytical HPLC prior to critical assays.
  • For quantitative biology (e.g., IC50 curves), confirm concentration by an orthogonal method (e.g., quantitative NMR or extinction coefficient calibration) if the CoA does not provide such data.
  • Record lot numbers and retain CoAs with experimental records for data traceability.
Reaction and Applications

Scope of use: This product is a bioactive small-molecule research tool labeled as an “ERK1/2 inhibitor.” It is intended for biochemical/cellular studies rather than as a synthetic reagent. No manufacturer application notes are provided in the listing.

Applicable research applications (general guidance, not item-specific claims):

  • Pathway interrogation: Modulation of ERK1/2 activity in MAPK signaling studies, time-course phosphorylation experiments (e.g., p-ERK, p-RSK readouts), and feedback-loop investigations.
  • Assay development: Positive/negative control in ERK enzyme assays, cellular reporter assays (e.g., SRE/ELK1-based), and high-content imaging of pathway activation states.
  • Chemical biology: Probe-dependent phenotyping, combination studies with RAF/MEK inhibitors to dissect pathway topology.

Not applicable as a reagent for named organic reactions: This compound is not typically used in syntheses (e.g., Grignard, cross-coupling). If chemical modification is intended, obtain structural data and ensure IP/compliance.

Practical tips:

  • Validate target engagement with orthogonal methods (e.g., in vitro IC50 in purified enzyme assay and cellular target modulation via phospho-ERK Western blotting), acknowledging that item-specific potency and selectivity are unknown.
  • Titrate DMSO controls carefully; include vehicle-only wells.
  • Consider serum protein binding and efflux transporters in cellular assays; actual ADME properties for this item are not provided and must be empirically determined.
Reaction Conditions

Not applicable in the conventional synthetic sense: ERK1/2 inhibitor 11 is a finished small molecule for biological research, not a reagent used to run chemical reactions.

If performing biochemical reactions/assays (general guidance, not item-specific specifications):

  • Enzymatic assays: Typical conditions for ERK kinase assays include buffered aqueous systems (e.g., 25–50 mM HEPES pH 7.4), Mg2+ for ATPase activity, ATP at Km-relevant concentrations, and substrate peptides or proteins (e.g., RSK-derived peptides). Incubation times vary from 10–60 min at 25–37°C.
  • Inhibitor dosing: Prepare DMSO stocks and perform serial dilutions to achieve a range of concentrations for IC50 determination. Maintain constant DMSO across wells (often 0.1–1% final); exact tolerances depend on the assay.
  • Readouts: ADP-coupled assays, radiometric transfer, TR-FRET, or Western blot for p-ERK substrates are common.

These conditions are general literature practices and must be adapted/validated for your specific assay platform. No item-specific potency, kinetics, or stability data are provided here.

Safety and Handling

Safety data specific to this item are not supplied in the listing and must be obtained from the product SDS.

  • GHS/CLP classification: Not specified for this item; refer to SDS.
  • Signal word and H-statements: Not specified for this item; refer to SDS.
  • Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (good practice for small-molecule inhibitors):

  • Use in a chemical fume hood; avoid inhalation of dusts/aerosols and skin/eye contact.
  • Wear appropriate PPE: lab coat, safety glasses, and suitable chemical-resistant gloves. For weighed solids or when aerosolization is possible, consider a particle mask/respirator per institutional EHS guidance.
  • Avoid repeated freeze–thaw of DMSO stocks; aliquot to minimize exposure and degradation.
  • Incompatibilities: Avoid strong oxidizers and strong acids/bases unless compatibility is verified (general guidance).

First-aid (refer to SDS for authoritative instructions):

  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin contact: Wash with soap and water; remove contaminated clothing.
  • Eye contact: Rinse cautiously with water for several minutes; seek medical attention if irritation persists.
  • Ingestion: Rinse mouth; seek medical attention.

Waste and spill response:

  • Collect spills with inert absorbent. Dispose of waste according to local regulations and institutional SOPs for organic research chemicals.

Research use: For research use only. Not for human or veterinary use.

Solvent Selection

No item-specific solubility profile is provided. The following is general guidance for small-molecule kinase inhibitors in research workflows (background, not item-specific specifications):

  • Primary stock solvent: DMSO is commonly used due to broad solubilizing capacity and compatibility with biochemical and cell assays at low final % (typically ≤0.1–0.5%).
  • Alternative co-solvents: DMF or ethanol can be used if compatible with the assay; PEG400 or aqueous buffers with cyclodextrins are options to enhance solubility where needed.
  • Aqueous media: Many kinase inhibitors show limited solubility at neutral pH; modest solubility increases may occur in acidic or basic buffers if ionizable groups are present (unknown for this item).

Comparison (general):

  • DMSO vs DMF: DMSO is more commonly accepted for biological assays and has lower volatility; DMF may have higher cytotoxicity in some cells—use with caution.
  • DMSO vs ethanol: Ethanol evaporates faster and can cause precipitation in microplates; DMSO provides better stock stability.

Practical tips:

  • Prepare concentrated stocks (e.g., 10–50 mM) in DMSO, then dilute into assay buffer ensuring the final DMSO concentration is within assay tolerance.
  • If precipitation occurs on dilution, add the DMSO stock last under vigorous mixing, increase surfactant (e.g., 0.01% Tween-20 if assay-compatible), or use serial DMSO titrations.
  • Filter sterilize only if chemically compatible; adsorption onto membranes can cause loss—assess recovery.

Always confirm solvent compatibility experimentally for your specific assay.

Storage and Reconstitution

Storage conditions provided for this item:

  • Long-term storage: Store at −20°C.
  • Shipping: Ice chest + ice pads (as listed).

Additional handling guidance (general best practice for small-molecule inhibitors; not item-specific specifications):

  • Protect from moisture and light when feasible. Store in tightly sealed, chemically compatible containers with desiccant.
  • Upon receipt, allow the container to equilibrate to room temperature before opening to minimize condensation ingress.

Reconstitution (general suggestions):

  • Prepare concentrated stock solutions in anhydrous DMSO (e.g., 10–50 mM) unless the CoA specifies a different solvent.
  • Vortex and, if needed, sonicate briefly to dissolve. If insoluble, warm gently (≤37°C) and avoid prolonged heating.
  • Filter only if necessary and compatible; adsorption losses can be significant.
  • Aliquot stocks into single-use volumes to avoid repeated freeze–thaw cycles.

Stability notes:

  • Freeze DMSO stocks at −20°C or below in sealed vials; minimize headspace to limit moisture uptake.
  • Track storage history and discard solutions showing precipitation, discoloration, or assay drift.

For definitive stability, reconstitution solvent, and shelf-life, consult the product’s CoA and SDS. Research use only.

Structure and Identity

Brief overview: ERK1/2 inhibitor 11 is listed as a small-molecule screening library compound targeting the ERK1/2 kinase pathway. Item-specific structural identifiers have not been provided for this SKU.

  • Item-specific identifiers:

    • CAS: Not specified for this item; refer to CoA/Spec Sheet.
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Naming/Context:

    • Catalog Name: ERK1/2 inhibitor 11 (screening library/chemical probe candidate).
    • Category: Small molecules and compound libraries.
  • Structural description (general literature context, not item-specific):

    • ERK1/2 inhibitors in the literature commonly feature heteroaromatic scaffolds (e.g., imidazopyridazines, pyrimidines, quinazolines) with hinge-binding motifs, H-bond donors/acceptors for the ATP site, and lipophilic substituents that engage hydrophobic pockets. Some chemotypes are covalent allosteric binders to ERK1/2 with acrylamide warheads, though many are reversible ATP-competitive inhibitors.
  • Stereochemistry: Not specified for this item; refer to CoA/Spec Sheet.

Note: Because no structural identifiers are provided for this exact item, treat any literature scaffold discussion as general background only and consult the CoA/SDS for definitive identity data.

Synthetic Utility

This product is offered as a finished bioactive small molecule rather than as a general synthetic reagent or building block. No functional group details or reactivity profile are provided.

Accordingly:

  • Use as a substrate, catalyst, or coupling partner in synthetic organic reactions is not typical and is not supported by item-specific data.
  • If derivatization or probe synthesis is desired (e.g., biotinylation, photoaffinity tags), obtain the full structure and confirm compatibility with intended transformations (protecting-group strategies, stability to bases/acids/oxidants), then perform small-scale feasibility experiments.

General considerations for modifying kinase inhibitors (literature context, not item-specific):

  • ATP-site binders often possess heteroaromatics that tolerate late-stage amide couplings or SNAr at electron-deficient rings; however, such modifications can abolish potency/selectivity.
  • Handle with care under anhydrous/oxygen-controlled conditions only if the scaffold includes oxidation- or hydrolysis-sensitive moieties (unknown for this item).

Conclusion: Treat ERK1/2 inhibitor 11 as a research probe for biological experimentation rather than as a synthetic building block unless structural details are available and validated.

Target Specificity

Only the catalog name implies ERK1/2 pathway relevance; no validated target specificity data (e.g., Ki/IC50 values, selectivity panels, binding mode) are provided in the product data for this SKU.

  • Primary target: Not specified for this item; refer to CoA/Spec Sheet.
  • Selectivity profile: Not specified for this item; refer to CoA/Spec Sheet.
  • Binding mode (ATP-competitive/allosteric/covalent): Not specified for this item; refer to CoA/Spec Sheet.
  • Species cross-reactivity: Not specified for this item; refer to CoA/Spec Sheet.

Recommendation: Establish target engagement experimentally via orthogonal assays (biochemical ERK1/2 activity assays and cellular phospho-ERK readouts) and, if available, consult the CoA or supplier technical notes for any specificity data associated with this lot.

자주 묻는 질문

How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is E1418378, the molecular formula is C15H18N4O2S, and the molecular weight is 318.39 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.